 | | Vol. 14.04 – 31 January, 2023 |
| |
|
|
| Researchers studied 2,391 single-class I HLA-mismatched and 14,426 fully HLA-matched unrelated donor hematopoietic cell transplantation performed between 2008 and 2018 for acute leukemia or myelodysplastic syndromes.
[Journal of Clinical Oncology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To further investigate the impact of C1 inhibitor deficiency on activation of coagulation and thrombosis, scientists conducted studies using patient samples and mouse models.
[Blood] |
|
|
|
| By investigating alloantibodies to a high-prevalence antigen of unknown specificity, found in patients with a rare blood type, the authors showed that SLC44A2 was also expressed in red blood cells and carried a new blood group system.
[EMBO Molecular Medicine] |
|
|
|
| Scientists studied the expression of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD226 in a cohort of 115 chronic lymphocytic leukemia patients and reported the expression of TIGIT and CD226 by leukemic cells.
[Haematologica] |
|
|
|
| The authors utilized genetic and compound library screening approaches to identify rational combination treatment strategies to improve the use of vitamin C as adjuvant therapy for AML.
[Cell Reports] |
|
|
|
| Investigators showed a significant upregulation of EVA1A protein associated with the increase of endoplasmic reticulum stress during hematopoietic regeneration.
[Cell Death & Disease] |
| |
|
|
| To further assess the long-term benefits and risks of asciminib compared with those of bosutinib in patients with chronic myeloid leukemia in the chronic phase after ≥2 prior tyrosine kinase inhibitors, scientists reported efficacy and safety results in ASCEMBL after a median follow-up of 2.3 years.
[Leukemia] |
|
|
|
| Researchers investigated ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia, evaluating the tolerability of three sequencing regimens as well as overall safety and efficacy.
[Leukemia] |
|
|
|
| Scientists studied the prevalence and risk factors associated with pegylated (PEG)-asparaginase discontinuation in young adults with ALL treated in the US intergroup Cancer and Leukemia Group B (CALGB) 10403 study and examined the prognostic impact of early discontinuation on survival outcomes.
[Blood Advances] |
|
|
|
|
| Contrary to the classical path using growth factors to activate tissue regeneration, a novel strategy is emerging to prevent chemotherapy toxicity that involves the temporary cell-cycle arrest of normal cells, such as hematopoietic or epithelial precursors. This proactive approach may allow the sparing of the stem cell reserve of these tissues.
[Drugs & Aging] |
|
|
|
|
| The FDA announced draft guidelines that would do away with the current three-month abstinence requirement for donations from men who have sex with men. Potential donors would be screened with a questionnaire that evaluates their risks for HIV based on factors like sexual behavior and recent partners.
[Stat News] |
|
|
|
|
| February 9 – 12, 2023
Cancun, Mexico |
|
|
|
|
|
| | Swiss Federal Institute of Technology in Lausanne – Lausanne, Switzerland |
|
|
|
| | Dresden University of Technology – Dresden, Germany |
|
|
|
| | Lund University – Lund, Sweden |
|
|
|
| | Hebrew University of Jerusalem – Jerusalem, Israel |
|
|
|
| | Upstate Medical University – Syracuse, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
